nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—CYP3A7—Tacrolimus—atopic dermatitis	0.0371	0.0622	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Tacrolimus—atopic dermatitis	0.0371	0.0622	CbGbCtD
Sorafenib—CYP2C8—Mometasone—atopic dermatitis	0.0341	0.0572	CbGbCtD
Sorafenib—CYP3A5—Tacrolimus—atopic dermatitis	0.0278	0.0467	CbGbCtD
Sorafenib—CYP2B6—Diphenhydramine—atopic dermatitis	0.0258	0.0434	CbGbCtD
Sorafenib—ABCG2—Hydrocortisone—atopic dermatitis	0.0204	0.0343	CbGbCtD
Sorafenib—CYP2C8—Loratadine—atopic dermatitis	0.0196	0.0329	CbGbCtD
Sorafenib—CYP3A4—Pimecrolimus—atopic dermatitis	0.0182	0.0306	CbGbCtD
Sorafenib—ABCB1—Tacrolimus—atopic dermatitis	0.0181	0.0304	CbGbCtD
Sorafenib—CYP2C19—Loratadine—atopic dermatitis	0.0164	0.0276	CbGbCtD
Sorafenib—CYP2C19—Diphenhydramine—atopic dermatitis	0.0164	0.0276	CbGbCtD
Sorafenib—CYP1A2—Diphenhydramine—atopic dermatitis	0.0152	0.0254	CbGbCtD
Sorafenib—CYP3A7—Hydrocortisone—atopic dermatitis	0.0151	0.0253	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Hydrocortisone—atopic dermatitis	0.0151	0.0253	CbGbCtD
Sorafenib—ABCC2—Dexamethasone—atopic dermatitis	0.0141	0.0236	CbGbCtD
Sorafenib—CYP2C9—Loratadine—atopic dermatitis	0.0137	0.0229	CbGbCtD
Sorafenib—CYP2C9—Diphenhydramine—atopic dermatitis	0.0137	0.0229	CbGbCtD
Sorafenib—ABCB1—Loratadine—atopic dermatitis	0.0132	0.0222	CbGbCtD
Sorafenib—ABCG2—Dexamethasone—atopic dermatitis	0.0127	0.0213	CbGbCtD
Sorafenib—CYP2D6—Loratadine—atopic dermatitis	0.0125	0.021	CbGbCtD
Sorafenib—CYP2D6—Diphenhydramine—atopic dermatitis	0.0125	0.021	CbGbCtD
Sorafenib—ABCB1—Methylprednisolone—atopic dermatitis	0.0121	0.0203	CbGbCtD
Sorafenib—CYP3A5—Hydrocortisone—atopic dermatitis	0.0113	0.019	CbGbCtD
Sorafenib—CYP2C8—Hydrocortisone—atopic dermatitis	0.0109	0.0183	CbGbCtD
Sorafenib—CYP3A4—Tacrolimus—atopic dermatitis	0.0108	0.0182	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Dexamethasone—atopic dermatitis	0.00939	0.0158	CbGbCtD
Sorafenib—CYP3A7—Dexamethasone—atopic dermatitis	0.00939	0.0158	CbGbCtD
Sorafenib—CYP2C19—Prednisone—atopic dermatitis	0.0091	0.0153	CbGbCtD
Sorafenib—CYP2B6—Dexamethasone—atopic dermatitis	0.00894	0.015	CbGbCtD
Sorafenib—CYP3A4—Loratadine—atopic dermatitis	0.00794	0.0133	CbGbCtD
Sorafenib—ABCB1—Betamethasone—atopic dermatitis	0.00788	0.0132	CbGbCtD
Sorafenib—ABCB1—Prednisolone—atopic dermatitis	0.00777	0.013	CbGbCtD
Sorafenib—ABCB1—Hydrocortisone—atopic dermatitis	0.00737	0.0124	CbGbCtD
Sorafenib—ABCB1—Prednisone—atopic dermatitis	0.00734	0.0123	CbGbCtD
Sorafenib—CYP3A4—Methylprednisolone—atopic dermatitis	0.00726	0.0122	CbGbCtD
Sorafenib—CYP3A5—Dexamethasone—atopic dermatitis	0.00704	0.0118	CbGbCtD
Sorafenib—CYP2C8—Dexamethasone—atopic dermatitis	0.00677	0.0114	CbGbCtD
Sorafenib—CYP2C19—Dexamethasone—atopic dermatitis	0.00568	0.00953	CbGbCtD
Sorafenib—CYP3A4—Triamcinolone—atopic dermatitis	0.0055	0.00923	CbGbCtD
Sorafenib—CYP2C9—Dexamethasone—atopic dermatitis	0.00472	0.00793	CbGbCtD
Sorafenib—CYP3A4—Betamethasone—atopic dermatitis	0.00472	0.00792	CbGbCtD
Sorafenib—CYP3A4—Prednisolone—atopic dermatitis	0.00466	0.00782	CbGbCtD
Sorafenib—ABCB1—Dexamethasone—atopic dermatitis	0.00458	0.00769	CbGbCtD
Sorafenib—CYP3A4—Hydrocortisone—atopic dermatitis	0.00442	0.00741	CbGbCtD
Sorafenib—CYP3A4—Prednisone—atopic dermatitis	0.0044	0.00738	CbGbCtD
Sorafenib—CYP2D6—Dexamethasone—atopic dermatitis	0.00432	0.00725	CbGbCtD
Sorafenib—CDKL2—head—atopic dermatitis	0.00279	0.0608	CbGeAlD
Sorafenib—KIT—skin epidermis—atopic dermatitis	0.00276	0.0601	CbGeAlD
Sorafenib—CYP3A4—Dexamethasone—atopic dermatitis	0.00275	0.00461	CbGbCtD
Sorafenib—MAPK15—head—atopic dermatitis	0.00251	0.0547	CbGeAlD
Sorafenib—RET—neck—atopic dermatitis	0.002	0.0436	CbGeAlD
Sorafenib—FLT1—neck—atopic dermatitis	0.00176	0.0384	CbGeAlD
Sorafenib—RAF1—neck—atopic dermatitis	0.00175	0.0382	CbGeAlD
Sorafenib—KDR—neck—atopic dermatitis	0.00149	0.0325	CbGeAlD
Sorafenib—MAPK11—head—atopic dermatitis	0.00149	0.0324	CbGeAlD
Sorafenib—CDK7—head—atopic dermatitis	0.00146	0.0319	CbGeAlD
Sorafenib—AURKC—head—atopic dermatitis	0.00144	0.0314	CbGeAlD
Sorafenib—EPHA6—head—atopic dermatitis	0.00134	0.0291	CbGeAlD
Sorafenib—KIT—neck—atopic dermatitis	0.00132	0.0288	CbGeAlD
Sorafenib—PDGFRB—neck—atopic dermatitis	0.00129	0.0281	CbGeAlD
Sorafenib—ZAK—head—atopic dermatitis	0.00127	0.0276	CbGeAlD
Sorafenib—MAP3K19—head—atopic dermatitis	0.00121	0.0265	CbGeAlD
Sorafenib—TIE1—head—atopic dermatitis	0.00116	0.0252	CbGeAlD
Sorafenib—RAF1—skin of body—atopic dermatitis	0.00113	0.0247	CbGeAlD
Sorafenib—EPHB6—skin of body—atopic dermatitis	0.00113	0.0246	CbGeAlD
Sorafenib—FLT4—head—atopic dermatitis	0.000957	0.0209	CbGeAlD
Sorafenib—CSF1R—skin of body—atopic dermatitis	0.00094	0.0205	CbGeAlD
Sorafenib—MKNK2—head—atopic dermatitis	0.000866	0.0189	CbGeAlD
Sorafenib—MKNK1—head—atopic dermatitis	0.000855	0.0186	CbGeAlD
Sorafenib—KIT—skin of body—atopic dermatitis	0.000854	0.0186	CbGeAlD
Sorafenib—RET—head—atopic dermatitis	0.000845	0.0184	CbGeAlD
Sorafenib—PDGFRB—skin of body—atopic dermatitis	0.000834	0.0182	CbGeAlD
Sorafenib—RALBP1—head—atopic dermatitis	0.000782	0.017	CbGeAlD
Sorafenib—FLT1—head—atopic dermatitis	0.000744	0.0162	CbGeAlD
Sorafenib—RAF1—head—atopic dermatitis	0.000739	0.0161	CbGeAlD
Sorafenib—EPHB6—head—atopic dermatitis	0.000735	0.016	CbGeAlD
Sorafenib—STK10—head—atopic dermatitis	0.000704	0.0153	CbGeAlD
Sorafenib—PDGFRA—head—atopic dermatitis	0.000697	0.0152	CbGeAlD
Sorafenib—HTR2B—skin of body—atopic dermatitis	0.000661	0.0144	CbGeAlD
Sorafenib—KDR—head—atopic dermatitis	0.000629	0.0137	CbGeAlD
Sorafenib—MAP2K5—head—atopic dermatitis	0.000629	0.0137	CbGeAlD
Sorafenib—CSF1R—head—atopic dermatitis	0.000614	0.0134	CbGeAlD
Sorafenib—KIT—head—atopic dermatitis	0.000557	0.0121	CbGeAlD
Sorafenib—PDGFRB—head—atopic dermatitis	0.000544	0.0119	CbGeAlD
Sorafenib—HTR2C—head—atopic dermatitis	0.000459	0.01	CbGeAlD
Sorafenib—ABCC4—head—atopic dermatitis	0.000433	0.00945	CbGeAlD
Sorafenib—CYP2B6—skin of body—atopic dermatitis	0.000432	0.00943	CbGeAlD
Sorafenib—HTR2B—head—atopic dermatitis	0.000431	0.0094	CbGeAlD
Sorafenib—CYP2B6—head—atopic dermatitis	0.000282	0.00615	CbGeAlD
Sorafenib—CYP2D6—head—atopic dermatitis	0.00021	0.00457	CbGeAlD
Sorafenib—ABCB1—head—atopic dermatitis	0.000151	0.00329	CbGeAlD
Sorafenib—Arrhythmia—Hydrocortisone—atopic dermatitis	0.000151	0.000702	CcSEcCtD
Sorafenib—Erythema—Prednisolone—atopic dermatitis	0.00015	0.0007	CcSEcCtD
Sorafenib—Nausea—Fluocinolone Acetonide—atopic dermatitis	0.00015	0.000699	CcSEcCtD
Sorafenib—Mental disorder—Hydrocortisone—atopic dermatitis	0.000148	0.000688	CcSEcCtD
Sorafenib—Cardiac disorder—Methylprednisolone—atopic dermatitis	0.000147	0.000685	CcSEcCtD
Sorafenib—Erythema—Hydrocortisone—atopic dermatitis	0.000147	0.000684	CcSEcCtD
Sorafenib—Malnutrition—Hydrocortisone—atopic dermatitis	0.000147	0.000684	CcSEcCtD
Sorafenib—Neutropenia—Prednisone—atopic dermatitis	0.000147	0.000683	CcSEcCtD
Sorafenib—Haemoglobin—Dexamethasone—atopic dermatitis	0.000145	0.000675	CcSEcCtD
Sorafenib—Haemoglobin—Betamethasone—atopic dermatitis	0.000145	0.000675	CcSEcCtD
Sorafenib—Erectile dysfunction—Prednisone—atopic dermatitis	0.000144	0.000673	CcSEcCtD
Sorafenib—Haemorrhage—Betamethasone—atopic dermatitis	0.000144	0.000671	CcSEcCtD
Sorafenib—Haemorrhage—Dexamethasone—atopic dermatitis	0.000144	0.000671	CcSEcCtD
Sorafenib—Angiopathy—Methylprednisolone—atopic dermatitis	0.000144	0.00067	CcSEcCtD
Sorafenib—Nausea—Mometasone—atopic dermatitis	0.000143	0.000668	CcSEcCtD
Sorafenib—Immune system disorder—Methylprednisolone—atopic dermatitis	0.000143	0.000667	CcSEcCtD
Sorafenib—Mediastinal disorder—Methylprednisolone—atopic dermatitis	0.000143	0.000665	CcSEcCtD
Sorafenib—Arrhythmia—Triamcinolone—atopic dermatitis	0.000142	0.000661	CcSEcCtD
Sorafenib—Weight decreased—Prednisone—atopic dermatitis	0.000142	0.000661	CcSEcCtD
Sorafenib—Arrhythmia—Methylprednisolone—atopic dermatitis	0.000142	0.000659	CcSEcCtD
Sorafenib—Hypersensitivity—Tacrolimus—atopic dermatitis	0.000142	0.000659	CcSEcCtD
Sorafenib—Mental disorder—Methylprednisolone—atopic dermatitis	0.000139	0.000647	CcSEcCtD
Sorafenib—Erythema—Triamcinolone—atopic dermatitis	0.000138	0.000644	CcSEcCtD
Sorafenib—Malnutrition—Methylprednisolone—atopic dermatitis	0.000138	0.000643	CcSEcCtD
Sorafenib—Erythema—Methylprednisolone—atopic dermatitis	0.000138	0.000643	CcSEcCtD
Sorafenib—Asthenia—Tacrolimus—atopic dermatitis	0.000138	0.000642	CcSEcCtD
Sorafenib—Acute coronary syndrome—Prednisone—atopic dermatitis	0.000138	0.000642	CcSEcCtD
Sorafenib—Angioedema—Prednisolone—atopic dermatitis	0.000137	0.00064	CcSEcCtD
Sorafenib—Myocardial infarction—Prednisone—atopic dermatitis	0.000137	0.000638	CcSEcCtD
Sorafenib—Neuropathy peripheral—Prednisone—atopic dermatitis	0.000137	0.000638	CcSEcCtD
Sorafenib—Pruritus—Tacrolimus—atopic dermatitis	0.000136	0.000633	CcSEcCtD
Sorafenib—Dysgeusia—Triamcinolone—atopic dermatitis	0.000135	0.000631	CcSEcCtD
Sorafenib—Syncope—Prednisolone—atopic dermatitis	0.000135	0.000628	CcSEcCtD
Sorafenib—Angioedema—Hydrocortisone—atopic dermatitis	0.000134	0.000625	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisolone—atopic dermatitis	0.000132	0.000616	CcSEcCtD
Sorafenib—Syncope—Hydrocortisone—atopic dermatitis	0.000132	0.000613	CcSEcCtD
Sorafenib—Diarrhoea—Tacrolimus—atopic dermatitis	0.000131	0.000612	CcSEcCtD
Sorafenib—Angiopathy—Dexamethasone—atopic dermatitis	0.000131	0.000609	CcSEcCtD
Sorafenib—Angiopathy—Betamethasone—atopic dermatitis	0.000131	0.000609	CcSEcCtD
Sorafenib—Hypertension—Prednisolone—atopic dermatitis	0.00013	0.000605	CcSEcCtD
Sorafenib—Loss of consciousness—Hydrocortisone—atopic dermatitis	0.000129	0.000601	CcSEcCtD
Sorafenib—Arrhythmia—Betamethasone—atopic dermatitis	0.000129	0.0006	CcSEcCtD
Sorafenib—Arrhythmia—Dexamethasone—atopic dermatitis	0.000129	0.0006	CcSEcCtD
Sorafenib—Alopecia—Dexamethasone—atopic dermatitis	0.000127	0.000593	CcSEcCtD
Sorafenib—Alopecia—Betamethasone—atopic dermatitis	0.000127	0.000593	CcSEcCtD
Sorafenib—Dizziness—Tacrolimus—atopic dermatitis	0.000127	0.000592	CcSEcCtD
Sorafenib—Hypertension—Hydrocortisone—atopic dermatitis	0.000127	0.000591	CcSEcCtD
Sorafenib—Angioedema—Triamcinolone—atopic dermatitis	0.000126	0.000588	CcSEcCtD
Sorafenib—Haemoglobin—Prednisone—atopic dermatitis	0.000126	0.000588	CcSEcCtD
Sorafenib—Angioedema—Methylprednisolone—atopic dermatitis	0.000126	0.000587	CcSEcCtD
Sorafenib—Haemorrhage—Prednisone—atopic dermatitis	0.000125	0.000585	CcSEcCtD
Sorafenib—Erythema—Dexamethasone—atopic dermatitis	0.000125	0.000584	CcSEcCtD
Sorafenib—Erythema—Betamethasone—atopic dermatitis	0.000125	0.000584	CcSEcCtD
Sorafenib—Myalgia—Hydrocortisone—atopic dermatitis	0.000125	0.000582	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	0.000124	0.000578	CcSEcCtD
Sorafenib—Syncope—Triamcinolone—atopic dermatitis	0.000124	0.000578	CcSEcCtD
Sorafenib—Syncope—Methylprednisolone—atopic dermatitis	0.000124	0.000576	CcSEcCtD
Sorafenib—Connective tissue disorder—Prednisone—atopic dermatitis	0.000123	0.000574	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisolone—atopic dermatitis	0.000123	0.000572	CcSEcCtD
Sorafenib—Vomiting—Tacrolimus—atopic dermatitis	0.000122	0.000569	CcSEcCtD
Sorafenib—Loss of consciousness—Triamcinolone—atopic dermatitis	0.000122	0.000566	CcSEcCtD
Sorafenib—Loss of consciousness—Methylprednisolone—atopic dermatitis	0.000121	0.000565	CcSEcCtD
Sorafenib—Rash—Tacrolimus—atopic dermatitis	0.000121	0.000564	CcSEcCtD
Sorafenib—Dermatitis—Tacrolimus—atopic dermatitis	0.000121	0.000564	CcSEcCtD
Sorafenib—Shock—Prednisolone—atopic dermatitis	0.000121	0.000562	CcSEcCtD
Sorafenib—Cough—Triamcinolone—atopic dermatitis	0.000121	0.000562	CcSEcCtD
Sorafenib—Headache—Tacrolimus—atopic dermatitis	0.00012	0.000561	CcSEcCtD
Sorafenib—Anaphylactic shock—Hydrocortisone—atopic dermatitis	0.00012	0.000558	CcSEcCtD
Sorafenib—Hypertension—Triamcinolone—atopic dermatitis	0.000119	0.000556	CcSEcCtD
Sorafenib—Hypertension—Methylprednisolone—atopic dermatitis	0.000119	0.000555	CcSEcCtD
Sorafenib—Infection—Hydrocortisone—atopic dermatitis	0.000119	0.000555	CcSEcCtD
Sorafenib—Shock—Hydrocortisone—atopic dermatitis	0.000118	0.000549	CcSEcCtD
Sorafenib—Myalgia—Triamcinolone—atopic dermatitis	0.000118	0.000548	CcSEcCtD
Sorafenib—Nervous system disorder—Hydrocortisone—atopic dermatitis	0.000118	0.000547	CcSEcCtD
Sorafenib—Arthralgia—Methylprednisolone—atopic dermatitis	0.000117	0.000547	CcSEcCtD
Sorafenib—Myalgia—Methylprednisolone—atopic dermatitis	0.000117	0.000547	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	0.000117	0.000543	CcSEcCtD
Sorafenib—Flushing—Prednisone—atopic dermatitis	0.000116	0.000543	CcSEcCtD
Sorafenib—Skin disorder—Hydrocortisone—atopic dermatitis	0.000116	0.000542	CcSEcCtD
Sorafenib—Dry mouth—Triamcinolone—atopic dermatitis	0.000115	0.000536	CcSEcCtD
Sorafenib—Angioedema—Dexamethasone—atopic dermatitis	0.000115	0.000534	CcSEcCtD
Sorafenib—Angioedema—Betamethasone—atopic dermatitis	0.000115	0.000534	CcSEcCtD
Sorafenib—Anorexia—Hydrocortisone—atopic dermatitis	0.000114	0.000532	CcSEcCtD
Sorafenib—Nausea—Tacrolimus—atopic dermatitis	0.000114	0.000532	CcSEcCtD
Sorafenib—Angiopathy—Prednisone—atopic dermatitis	0.000114	0.00053	CcSEcCtD
Sorafenib—Immune system disorder—Prednisone—atopic dermatitis	0.000113	0.000528	CcSEcCtD
Sorafenib—Anaphylactic shock—Triamcinolone—atopic dermatitis	0.000113	0.000526	CcSEcCtD
Sorafenib—Anaphylactic shock—Methylprednisolone—atopic dermatitis	0.000113	0.000524	CcSEcCtD
Sorafenib—Syncope—Dexamethasone—atopic dermatitis	0.000112	0.000524	CcSEcCtD
Sorafenib—Syncope—Betamethasone—atopic dermatitis	0.000112	0.000524	CcSEcCtD
Sorafenib—Arrhythmia—Prednisone—atopic dermatitis	0.000112	0.000522	CcSEcCtD
Sorafenib—Infection—Triamcinolone—atopic dermatitis	0.000112	0.000522	CcSEcCtD
Sorafenib—Infection—Methylprednisolone—atopic dermatitis	0.000112	0.000521	CcSEcCtD
Sorafenib—Shock—Triamcinolone—atopic dermatitis	0.000111	0.000517	CcSEcCtD
Sorafenib—Alopecia—Prednisone—atopic dermatitis	0.000111	0.000517	CcSEcCtD
Sorafenib—Shock—Methylprednisolone—atopic dermatitis	0.000111	0.000516	CcSEcCtD
Sorafenib—Nervous system disorder—Methylprednisolone—atopic dermatitis	0.00011	0.000514	CcSEcCtD
Sorafenib—Loss of consciousness—Betamethasone—atopic dermatitis	0.00011	0.000514	CcSEcCtD
Sorafenib—Loss of consciousness—Dexamethasone—atopic dermatitis	0.00011	0.000514	CcSEcCtD
Sorafenib—Mental disorder—Prednisone—atopic dermatitis	0.00011	0.000512	CcSEcCtD
Sorafenib—Skin disorder—Methylprednisolone—atopic dermatitis	0.000109	0.000509	CcSEcCtD
Sorafenib—Erythema—Prednisone—atopic dermatitis	0.000109	0.000509	CcSEcCtD
Sorafenib—Malnutrition—Prednisone—atopic dermatitis	0.000109	0.000509	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	0.000109	0.000509	CcSEcCtD
Sorafenib—Hypertension—Dexamethasone—atopic dermatitis	0.000108	0.000505	CcSEcCtD
Sorafenib—Hypertension—Betamethasone—atopic dermatitis	0.000108	0.000505	CcSEcCtD
Sorafenib—Myalgia—Betamethasone—atopic dermatitis	0.000107	0.000497	CcSEcCtD
Sorafenib—Myalgia—Dexamethasone—atopic dermatitis	0.000107	0.000497	CcSEcCtD
Sorafenib—Dyspepsia—Hydrocortisone—atopic dermatitis	0.000105	0.000491	CcSEcCtD
Sorafenib—Pain—Prednisolone—atopic dermatitis	0.000105	0.000489	CcSEcCtD
Sorafenib—Decreased appetite—Hydrocortisone—atopic dermatitis	0.000104	0.000485	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	0.000103	0.000482	CcSEcCtD
Sorafenib—Fatigue—Hydrocortisone—atopic dermatitis	0.000103	0.000481	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	0.000103	0.000479	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	0.000103	0.000478	CcSEcCtD
Sorafenib—Pain—Hydrocortisone—atopic dermatitis	0.000102	0.000477	CcSEcCtD
Sorafenib—Anaphylactic shock—Betamethasone—atopic dermatitis	0.000102	0.000477	CcSEcCtD
Sorafenib—Anaphylactic shock—Dexamethasone—atopic dermatitis	0.000102	0.000477	CcSEcCtD
Sorafenib—Infection—Dexamethasone—atopic dermatitis	0.000102	0.000474	CcSEcCtD
Sorafenib—Infection—Betamethasone—atopic dermatitis	0.000102	0.000474	CcSEcCtD
Sorafenib—Anaemia—Prednisone—atopic dermatitis	0.000101	0.00047	CcSEcCtD
Sorafenib—Shock—Dexamethasone—atopic dermatitis	0.000101	0.000469	CcSEcCtD
Sorafenib—Shock—Betamethasone—atopic dermatitis	0.000101	0.000469	CcSEcCtD
Sorafenib—Dyspnoea—Triamcinolone—atopic dermatitis	0.000101	0.000469	CcSEcCtD
Sorafenib—Nervous system disorder—Dexamethasone—atopic dermatitis	0.0001	0.000468	CcSEcCtD
Sorafenib—Nervous system disorder—Betamethasone—atopic dermatitis	0.0001	0.000468	CcSEcCtD
Sorafenib—Thrombocytopenia—Betamethasone—atopic dermatitis	0.0001	0.000467	CcSEcCtD
Sorafenib—Thrombocytopenia—Dexamethasone—atopic dermatitis	0.0001	0.000467	CcSEcCtD
Sorafenib—Angioedema—Prednisone—atopic dermatitis	9.98e-05	0.000465	CcSEcCtD
Sorafenib—Dyspepsia—Triamcinolone—atopic dermatitis	9.93e-05	0.000463	CcSEcCtD
Sorafenib—Dyspepsia—Methylprednisolone—atopic dermatitis	9.91e-05	0.000462	CcSEcCtD
Sorafenib—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	9.8e-05	0.000456	CcSEcCtD
Sorafenib—Syncope—Prednisone—atopic dermatitis	9.8e-05	0.000456	CcSEcCtD
Sorafenib—Anorexia—Betamethasone—atopic dermatitis	9.76e-05	0.000455	CcSEcCtD
Sorafenib—Anorexia—Dexamethasone—atopic dermatitis	9.76e-05	0.000455	CcSEcCtD
Sorafenib—Urticaria—Prednisolone—atopic dermatitis	9.75e-05	0.000454	CcSEcCtD
Sorafenib—Fatigue—Triamcinolone—atopic dermatitis	9.73e-05	0.000453	CcSEcCtD
Sorafenib—Fatigue—Methylprednisolone—atopic dermatitis	9.71e-05	0.000452	CcSEcCtD
Sorafenib—Pain—Triamcinolone—atopic dermatitis	9.65e-05	0.000449	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisone—atopic dermatitis	9.6e-05	0.000447	CcSEcCtD
Sorafenib—Urticaria—Hydrocortisone—atopic dermatitis	9.52e-05	0.000443	CcSEcCtD
Sorafenib—Abdominal pain—Hydrocortisone—atopic dermatitis	9.47e-05	0.000441	CcSEcCtD
Sorafenib—Body temperature increased—Hydrocortisone—atopic dermatitis	9.47e-05	0.000441	CcSEcCtD
Sorafenib—Hypertension—Prednisone—atopic dermatitis	9.43e-05	0.000439	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	9.33e-05	0.000435	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	9.33e-05	0.000435	CcSEcCtD
Sorafenib—Arthralgia—Prednisone—atopic dermatitis	9.3e-05	0.000433	CcSEcCtD
Sorafenib—Myalgia—Prednisone—atopic dermatitis	9.3e-05	0.000433	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	9.24e-05	0.00043	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	9.21e-05	0.000429	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisolone—atopic dermatitis	9.04e-05	0.000421	CcSEcCtD
Sorafenib—Dyspepsia—Betamethasone—atopic dermatitis	9.01e-05	0.00042	CcSEcCtD
Sorafenib—Dyspepsia—Dexamethasone—atopic dermatitis	9.01e-05	0.00042	CcSEcCtD
Sorafenib—Urticaria—Triamcinolone—atopic dermatitis	8.96e-05	0.000418	CcSEcCtD
Sorafenib—Urticaria—Methylprednisolone—atopic dermatitis	8.94e-05	0.000417	CcSEcCtD
Sorafenib—Body temperature increased—Triamcinolone—atopic dermatitis	8.92e-05	0.000416	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisone—atopic dermatitis	8.92e-05	0.000415	CcSEcCtD
Sorafenib—Abdominal pain—Methylprednisolone—atopic dermatitis	8.9e-05	0.000415	CcSEcCtD
Sorafenib—Decreased appetite—Betamethasone—atopic dermatitis	8.9e-05	0.000415	CcSEcCtD
Sorafenib—Decreased appetite—Dexamethasone—atopic dermatitis	8.9e-05	0.000415	CcSEcCtD
Sorafenib—Infection—Prednisone—atopic dermatitis	8.86e-05	0.000413	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	8.84e-05	0.000412	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Betamethasone—atopic dermatitis	8.84e-05	0.000412	CcSEcCtD
Sorafenib—Hypersensitivity—Hydrocortisone—atopic dermatitis	8.83e-05	0.000411	CcSEcCtD
Sorafenib—Fatigue—Dexamethasone—atopic dermatitis	8.83e-05	0.000411	CcSEcCtD
Sorafenib—Fatigue—Betamethasone—atopic dermatitis	8.83e-05	0.000411	CcSEcCtD
Sorafenib—Shock—Prednisone—atopic dermatitis	8.77e-05	0.000409	CcSEcCtD
Sorafenib—Pain—Dexamethasone—atopic dermatitis	8.75e-05	0.000408	CcSEcCtD
Sorafenib—Pain—Betamethasone—atopic dermatitis	8.75e-05	0.000408	CcSEcCtD
Sorafenib—Nervous system disorder—Prednisone—atopic dermatitis	8.74e-05	0.000407	CcSEcCtD
Sorafenib—Skin disorder—Prednisone—atopic dermatitis	8.66e-05	0.000403	CcSEcCtD
Sorafenib—Asthenia—Hydrocortisone—atopic dermatitis	8.6e-05	0.000401	CcSEcCtD
Sorafenib—Anorexia—Prednisone—atopic dermatitis	8.5e-05	0.000396	CcSEcCtD
Sorafenib—Pruritus—Hydrocortisone—atopic dermatitis	8.48e-05	0.000395	CcSEcCtD
Sorafenib—Gastrointestinal pain—Betamethasone—atopic dermatitis	8.37e-05	0.00039	CcSEcCtD
Sorafenib—Gastrointestinal pain—Dexamethasone—atopic dermatitis	8.37e-05	0.00039	CcSEcCtD
Sorafenib—Hypersensitivity—Triamcinolone—atopic dermatitis	8.31e-05	0.000387	CcSEcCtD
Sorafenib—Hypersensitivity—Methylprednisolone—atopic dermatitis	8.29e-05	0.000386	CcSEcCtD
Sorafenib—Diarrhoea—Hydrocortisone—atopic dermatitis	8.2e-05	0.000382	CcSEcCtD
Sorafenib—Urticaria—Betamethasone—atopic dermatitis	8.13e-05	0.000379	CcSEcCtD
Sorafenib—Urticaria—Dexamethasone—atopic dermatitis	8.13e-05	0.000379	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Prednisone—atopic dermatitis	8.12e-05	0.000378	CcSEcCtD
Sorafenib—Dizziness—Prednisolone—atopic dermatitis	8.11e-05	0.000378	CcSEcCtD
Sorafenib—Asthenia—Triamcinolone—atopic dermatitis	8.1e-05	0.000377	CcSEcCtD
Sorafenib—Body temperature increased—Betamethasone—atopic dermatitis	8.09e-05	0.000377	CcSEcCtD
Sorafenib—Abdominal pain—Betamethasone—atopic dermatitis	8.09e-05	0.000377	CcSEcCtD
Sorafenib—Abdominal pain—Dexamethasone—atopic dermatitis	8.09e-05	0.000377	CcSEcCtD
Sorafenib—Body temperature increased—Dexamethasone—atopic dermatitis	8.09e-05	0.000377	CcSEcCtD
Sorafenib—Asthenia—Methylprednisolone—atopic dermatitis	8.08e-05	0.000376	CcSEcCtD
Sorafenib—Pruritus—Triamcinolone—atopic dermatitis	7.98e-05	0.000372	CcSEcCtD
Sorafenib—Pruritus—Methylprednisolone—atopic dermatitis	7.96e-05	0.000371	CcSEcCtD
Sorafenib—Dizziness—Hydrocortisone—atopic dermatitis	7.92e-05	0.000369	CcSEcCtD
Sorafenib—Dyspepsia—Prednisone—atopic dermatitis	7.85e-05	0.000366	CcSEcCtD
Sorafenib—Decreased appetite—Prednisone—atopic dermatitis	7.75e-05	0.000361	CcSEcCtD
Sorafenib—Rash—Prednisolone—atopic dermatitis	7.74e-05	0.00036	CcSEcCtD
Sorafenib—Dermatitis—Prednisolone—atopic dermatitis	7.73e-05	0.00036	CcSEcCtD
Sorafenib—Diarrhoea—Methylprednisolone—atopic dermatitis	7.7e-05	0.000359	CcSEcCtD
Sorafenib—Fatigue—Prednisone—atopic dermatitis	7.69e-05	0.000358	CcSEcCtD
Sorafenib—Headache—Prednisolone—atopic dermatitis	7.69e-05	0.000358	CcSEcCtD
Sorafenib—Constipation—Prednisone—atopic dermatitis	7.62e-05	0.000355	CcSEcCtD
Sorafenib—Vomiting—Hydrocortisone—atopic dermatitis	7.62e-05	0.000355	CcSEcCtD
Sorafenib—Rash—Hydrocortisone—atopic dermatitis	7.56e-05	0.000352	CcSEcCtD
Sorafenib—Dermatitis—Hydrocortisone—atopic dermatitis	7.55e-05	0.000352	CcSEcCtD
Sorafenib—Headache—Hydrocortisone—atopic dermatitis	7.51e-05	0.00035	CcSEcCtD
Sorafenib—Dizziness—Triamcinolone—atopic dermatitis	7.46e-05	0.000348	CcSEcCtD
Sorafenib—Dizziness—Methylprednisolone—atopic dermatitis	7.44e-05	0.000347	CcSEcCtD
Sorafenib—Asthenia—Dexamethasone—atopic dermatitis	7.35e-05	0.000342	CcSEcCtD
Sorafenib—Asthenia—Betamethasone—atopic dermatitis	7.35e-05	0.000342	CcSEcCtD
Sorafenib—Gastrointestinal pain—Prednisone—atopic dermatitis	7.29e-05	0.00034	CcSEcCtD
Sorafenib—Nausea—Prednisolone—atopic dermatitis	7.29e-05	0.000339	CcSEcCtD
Sorafenib—Pruritus—Betamethasone—atopic dermatitis	7.24e-05	0.000337	CcSEcCtD
Sorafenib—Pruritus—Dexamethasone—atopic dermatitis	7.24e-05	0.000337	CcSEcCtD
Sorafenib—Vomiting—Triamcinolone—atopic dermatitis	7.17e-05	0.000334	CcSEcCtD
Sorafenib—Vomiting—Methylprednisolone—atopic dermatitis	7.16e-05	0.000333	CcSEcCtD
Sorafenib—Nausea—Hydrocortisone—atopic dermatitis	7.12e-05	0.000332	CcSEcCtD
Sorafenib—Rash—Triamcinolone—atopic dermatitis	7.11e-05	0.000331	CcSEcCtD
Sorafenib—Dermatitis—Triamcinolone—atopic dermatitis	7.11e-05	0.000331	CcSEcCtD
Sorafenib—Rash—Methylprednisolone—atopic dermatitis	7.1e-05	0.000331	CcSEcCtD
Sorafenib—Dermatitis—Methylprednisolone—atopic dermatitis	7.09e-05	0.00033	CcSEcCtD
Sorafenib—Urticaria—Prednisone—atopic dermatitis	7.08e-05	0.00033	CcSEcCtD
Sorafenib—Headache—Triamcinolone—atopic dermatitis	7.07e-05	0.000329	CcSEcCtD
Sorafenib—Headache—Methylprednisolone—atopic dermatitis	7.05e-05	0.000329	CcSEcCtD
Sorafenib—Abdominal pain—Prednisone—atopic dermatitis	7.05e-05	0.000328	CcSEcCtD
Sorafenib—Body temperature increased—Prednisone—atopic dermatitis	7.05e-05	0.000328	CcSEcCtD
Sorafenib—Diarrhoea—Betamethasone—atopic dermatitis	7e-05	0.000326	CcSEcCtD
Sorafenib—Diarrhoea—Dexamethasone—atopic dermatitis	7e-05	0.000326	CcSEcCtD
Sorafenib—Dizziness—Betamethasone—atopic dermatitis	6.77e-05	0.000315	CcSEcCtD
Sorafenib—Dizziness—Dexamethasone—atopic dermatitis	6.77e-05	0.000315	CcSEcCtD
Sorafenib—Nausea—Triamcinolone—atopic dermatitis	6.7e-05	0.000312	CcSEcCtD
Sorafenib—Nausea—Methylprednisolone—atopic dermatitis	6.69e-05	0.000312	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisone—atopic dermatitis	6.57e-05	0.000306	CcSEcCtD
Sorafenib—Vomiting—Dexamethasone—atopic dermatitis	6.51e-05	0.000303	CcSEcCtD
Sorafenib—Vomiting—Betamethasone—atopic dermatitis	6.51e-05	0.000303	CcSEcCtD
Sorafenib—Rash—Betamethasone—atopic dermatitis	6.45e-05	0.000301	CcSEcCtD
Sorafenib—Rash—Dexamethasone—atopic dermatitis	6.45e-05	0.000301	CcSEcCtD
Sorafenib—Dermatitis—Betamethasone—atopic dermatitis	6.45e-05	0.0003	CcSEcCtD
Sorafenib—Dermatitis—Dexamethasone—atopic dermatitis	6.45e-05	0.0003	CcSEcCtD
Sorafenib—Headache—Dexamethasone—atopic dermatitis	6.41e-05	0.000299	CcSEcCtD
Sorafenib—Headache—Betamethasone—atopic dermatitis	6.41e-05	0.000299	CcSEcCtD
Sorafenib—Asthenia—Prednisone—atopic dermatitis	6.4e-05	0.000298	CcSEcCtD
Sorafenib—Pruritus—Prednisone—atopic dermatitis	6.31e-05	0.000294	CcSEcCtD
Sorafenib—Diarrhoea—Prednisone—atopic dermatitis	6.1e-05	0.000284	CcSEcCtD
Sorafenib—Nausea—Dexamethasone—atopic dermatitis	6.08e-05	0.000283	CcSEcCtD
Sorafenib—Nausea—Betamethasone—atopic dermatitis	6.08e-05	0.000283	CcSEcCtD
Sorafenib—Dizziness—Prednisone—atopic dermatitis	5.9e-05	0.000275	CcSEcCtD
Sorafenib—Vomiting—Prednisone—atopic dermatitis	5.67e-05	0.000264	CcSEcCtD
Sorafenib—Rash—Prednisone—atopic dermatitis	5.62e-05	0.000262	CcSEcCtD
Sorafenib—Dermatitis—Prednisone—atopic dermatitis	5.62e-05	0.000262	CcSEcCtD
Sorafenib—Headache—Prednisone—atopic dermatitis	5.59e-05	0.00026	CcSEcCtD
Sorafenib—Nausea—Prednisone—atopic dermatitis	5.3e-05	0.000247	CcSEcCtD
Sorafenib—RAF1—Immune System—CD8A—atopic dermatitis	1.42e-05	9.89e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—CD4—atopic dermatitis	1.4e-05	9.75e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GLB1—atopic dermatitis	1.4e-05	9.74e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NFKBIA—atopic dermatitis	1.38e-05	9.57e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ADSL—atopic dermatitis	1.37e-05	9.57e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL2—atopic dermatitis	1.37e-05	9.57e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NFKBIA—atopic dermatitis	1.37e-05	9.55e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TAC1—atopic dermatitis	1.37e-05	9.51e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NPS—atopic dermatitis	1.37e-05	9.51e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CCL5—atopic dermatitis	1.36e-05	9.48e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CCL5—atopic dermatitis	1.36e-05	9.47e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL5—atopic dermatitis	1.36e-05	9.46e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	1.35e-05	9.43e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CXCL10—atopic dermatitis	1.35e-05	9.41e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CCR5—atopic dermatitis	1.35e-05	9.41e-05	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—IL6—atopic dermatitis	1.35e-05	9.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CXCL10—atopic dermatitis	1.35e-05	9.39e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CCL5—atopic dermatitis	1.35e-05	9.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CCR5—atopic dermatitis	1.35e-05	9.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CD4—atopic dermatitis	1.35e-05	9.36e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ADSL—atopic dermatitis	1.34e-05	9.34e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCR3—atopic dermatitis	1.34e-05	9.33e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—MAPK8—atopic dermatitis	1.33e-05	9.27e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—IL6—atopic dermatitis	1.33e-05	9.25e-05	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—TNF—atopic dermatitis	1.33e-05	9.24e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCR3—atopic dermatitis	1.32e-05	9.21e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GLB1—atopic dermatitis	1.32e-05	9.18e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GLB1—atopic dermatitis	1.31e-05	9.1e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—CASP8—atopic dermatitis	1.31e-05	9.1e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CASP8—atopic dermatitis	1.31e-05	9.1e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—CXCL8—atopic dermatitis	1.3e-05	9.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL5—atopic dermatitis	1.27e-05	8.84e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—MAPK8—atopic dermatitis	1.27e-05	8.81e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ADSL—atopic dermatitis	1.26e-05	8.8e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NGF—atopic dermatitis	1.26e-05	8.77e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ADSL—atopic dermatitis	1.25e-05	8.73e-05	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—IL6—atopic dermatitis	1.25e-05	8.71e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NGF—atopic dermatitis	1.25e-05	8.69e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CASP8—atopic dermatitis	1.24e-05	8.64e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NFKBIA—atopic dermatitis	1.24e-05	8.63e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL2—atopic dermatitis	1.24e-05	8.62e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CASP8—atopic dermatitis	1.24e-05	8.61e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NFKBIA—atopic dermatitis	1.24e-05	8.6e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IFNG—atopic dermatitis	1.23e-05	8.58e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CCR5—atopic dermatitis	1.23e-05	8.54e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCL5—atopic dermatitis	1.23e-05	8.54e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCL5—atopic dermatitis	1.23e-05	8.54e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CCR5—atopic dermatitis	1.23e-05	8.53e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL10—atopic dermatitis	1.22e-05	8.46e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CCR5—atopic dermatitis	1.21e-05	8.45e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NFKBIA—atopic dermatitis	1.21e-05	8.41e-05	CbGpPWpGaD
Sorafenib—RAF1—Axon guidance—IL6—atopic dermatitis	1.2e-05	8.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CCR5—atopic dermatitis	1.2e-05	8.35e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD4—atopic dermatitis	1.19e-05	8.29e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—MAPK8—atopic dermatitis	1.19e-05	8.26e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NPS—atopic dermatitis	1.18e-05	8.21e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TAC1—atopic dermatitis	1.18e-05	8.21e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.17e-05	8.15e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCL5—atopic dermatitis	1.16e-05	8.1e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCL5—atopic dermatitis	1.16e-05	8.08e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL10—atopic dermatitis	1.16e-05	8.07e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCR3—atopic dermatitis	1.16e-05	8.05e-05	CbGpPWpGaD
Sorafenib—MKNK1—Disease—IL6—atopic dermatitis	1.15e-05	8.03e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—MAPK8—atopic dermatitis	1.14e-05	7.93e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NGF—atopic dermatitis	1.14e-05	7.91e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NGF—atopic dermatitis	1.14e-05	7.91e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GLB1—atopic dermatitis	1.12e-05	7.78e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CASP8—atopic dermatitis	1.11e-05	7.76e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IFNG—atopic dermatitis	1.11e-05	7.74e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IFNG—atopic dermatitis	1.11e-05	7.74e-05	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—IL6—atopic dermatitis	1.11e-05	7.69e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCR5—atopic dermatitis	1.11e-05	7.69e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCR5—atopic dermatitis	1.11e-05	7.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NFKBIA—atopic dermatitis	1.1e-05	7.67e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL1B—atopic dermatitis	1.1e-05	7.65e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL5—atopic dermatitis	1.1e-05	7.63e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL2—atopic dermatitis	1.1e-05	7.62e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—CD4—atopic dermatitis	1.09e-05	7.58e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL10—atopic dermatitis	1.08e-05	7.54e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NGF—atopic dermatitis	1.08e-05	7.51e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NGF—atopic dermatitis	1.08e-05	7.49e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD4—atopic dermatitis	1.07e-05	7.47e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD4—atopic dermatitis	1.07e-05	7.47e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	1.07e-05	7.46e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ADSL—atopic dermatitis	1.07e-05	7.46e-05	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—IL6—atopic dermatitis	1.07e-05	7.46e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—TNF—atopic dermatitis	1.06e-05	7.4e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IFNG—atopic dermatitis	1.05e-05	7.34e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IFNG—atopic dermatitis	1.05e-05	7.32e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCR5—atopic dermatitis	1.05e-05	7.3e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCR5—atopic dermatitis	1.05e-05	7.28e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCL5—atopic dermatitis	1.05e-05	7.28e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.04e-05	7.27e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NFKBIA—atopic dermatitis	1.04e-05	7.23e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NFKBIA—atopic dermatitis	1.03e-05	7.17e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD4—atopic dermatitis	1.02e-05	7.09e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD4—atopic dermatitis	1.02e-05	7.07e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—CXCL8—atopic dermatitis	1.01e-05	7.05e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—MAPK8—atopic dermatitis	1.01e-05	7.02e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCL5—atopic dermatitis	9.98e-06	6.95e-05	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—IL6—atopic dermatitis	9.97e-06	6.94e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—IL6—atopic dermatitis	9.97e-06	6.94e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CASP8—atopic dermatitis	9.94e-06	6.92e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL1B—atopic dermatitis	9.91e-06	6.9e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL1B—atopic dermatitis	9.91e-06	6.9e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—IL6—atopic dermatitis	9.91e-06	6.9e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—CD4—atopic dermatitis	9.91e-06	6.9e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PPARA—atopic dermatitis	9.9e-06	6.89e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PPARA—atopic dermatitis	9.9e-06	6.89e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL2—atopic dermatitis	9.88e-06	6.88e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL2—atopic dermatitis	9.88e-06	6.88e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—IL6—atopic dermatitis	9.75e-06	6.79e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	9.7e-06	6.75e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NGF—atopic dermatitis	9.69e-06	6.74e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—IL2—atopic dermatitis	9.68e-06	6.74e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	9.53e-06	6.63e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IFNG—atopic dermatitis	9.48e-06	6.6e-05	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—IL6—atopic dermatitis	9.46e-06	6.58e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—IL6—atopic dermatitis	9.43e-06	6.57e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCR5—atopic dermatitis	9.42e-06	6.56e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL1B—atopic dermatitis	9.41e-06	6.55e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CD4—atopic dermatitis	9.41e-06	6.55e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL1B—atopic dermatitis	9.38e-06	6.53e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CD4—atopic dermatitis	9.38e-06	6.53e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL2—atopic dermatitis	9.37e-06	6.52e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NFKBIA—atopic dermatitis	9.37e-06	6.52e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NFKBIA—atopic dermatitis	9.37e-06	6.52e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL10—atopic dermatitis	9.35e-06	6.51e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL2—atopic dermatitis	9.35e-06	6.51e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCL5—atopic dermatitis	9.32e-06	6.49e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NGF—atopic dermatitis	9.24e-06	6.43e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CXCL8—atopic dermatitis	9.2e-06	6.4e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD4—atopic dermatitis	9.15e-06	6.37e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—MAPK8—atopic dermatitis	9.09e-06	6.33e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—MAPK8—atopic dermatitis	9.09e-06	6.33e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCR5—atopic dermatitis	8.99e-06	6.26e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NFKBIA—atopic dermatitis	8.89e-06	6.19e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NFKBIA—atopic dermatitis	8.87e-06	6.17e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CXCL8—atopic dermatitis	8.84e-06	6.16e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL2—atopic dermatitis	8.79e-06	6.12e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NGF—atopic dermatitis	8.64e-06	6.01e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—MAPK8—atopic dermatitis	8.63e-06	6.01e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GLB1—atopic dermatitis	8.62e-06	6e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CXCL8—atopic dermatitis	8.62e-06	6e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—MAPK8—atopic dermatitis	8.61e-06	5.99e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CXCL8—atopic dermatitis	8.6e-06	5.98e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—IL6—atopic dermatitis	8.58e-06	5.97e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—IL6—atopic dermatitis	8.5e-06	5.92e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL1B—atopic dermatitis	8.45e-06	5.89e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CD4—atopic dermatitis	8.45e-06	5.88e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL2—atopic dermatitis	8.45e-06	5.88e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IFNG—atopic dermatitis	8.45e-06	5.88e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL2—atopic dermatitis	8.42e-06	5.86e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PPARA—atopic dermatitis	8.4e-06	5.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCR5—atopic dermatitis	8.4e-06	5.85e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PPARA—atopic dermatitis	8.33e-06	5.8e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADSL—atopic dermatitis	8.27e-06	5.75e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL2—atopic dermatitis	8.24e-06	5.73e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL2—atopic dermatitis	8.22e-06	5.72e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CXCL8—atopic dermatitis	8.17e-06	5.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD4—atopic dermatitis	8.16e-06	5.68e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	8.14e-06	5.67e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—atopic dermatitis	8.13e-06	5.66e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—atopic dermatitis	8.08e-06	5.62e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL5—atopic dermatitis	8.05e-06	5.6e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NFKBIA—atopic dermatitis	7.99e-06	5.56e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—IL2—atopic dermatitis	7.81e-06	5.44e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MAPK8—atopic dermatitis	7.78e-06	5.41e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—MAPK8—atopic dermatitis	7.75e-06	5.4e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NFKBIA—atopic dermatitis	7.62e-06	5.3e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MAPK8—atopic dermatitis	7.58e-06	5.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—atopic dermatitis	7.58e-06	5.27e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1B—atopic dermatitis	7.54e-06	5.25e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD4—atopic dermatitis	7.53e-06	5.24e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL2—atopic dermatitis	7.51e-06	5.23e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NGF—atopic dermatitis	7.45e-06	5.19e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CXCL8—atopic dermatitis	7.42e-06	5.17e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CXCL8—atopic dermatitis	7.41e-06	5.16e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CXCL8—atopic dermatitis	7.34e-06	5.11e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—atopic dermatitis	7.27e-06	5.06e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCR5—atopic dermatitis	7.25e-06	5.05e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NFKBIA—atopic dermatitis	7.12e-06	4.96e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL2—atopic dermatitis	7.09e-06	4.94e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL2—atopic dermatitis	7.08e-06	4.93e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL2—atopic dermatitis	7.02e-06	4.88e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—MAPK8—atopic dermatitis	6.91e-06	4.81e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CXCL8—atopic dermatitis	6.68e-06	4.65e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CXCL8—atopic dermatitis	6.68e-06	4.65e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MAPK8—atopic dermatitis	6.52e-06	4.54e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MAPK8—atopic dermatitis	6.46e-06	4.5e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—atopic dermatitis	6.44e-06	4.48e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL2—atopic dermatitis	6.39e-06	4.45e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL2—atopic dermatitis	6.39e-06	4.45e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CXCL8—atopic dermatitis	6.34e-06	4.41e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CXCL8—atopic dermatitis	6.32e-06	4.4e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARA—atopic dermatitis	6.16e-06	4.29e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NFKBIA—atopic dermatitis	6.15e-06	4.28e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2—atopic dermatitis	6.06e-06	4.22e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2—atopic dermatitis	6.04e-06	4.21e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARA—atopic dermatitis	6.02e-06	4.19e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—atopic dermatitis	5.89e-06	4.1e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK8—atopic dermatitis	5.88e-06	4.09e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK8—atopic dermatitis	5.88e-06	4.09e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—atopic dermatitis	5.81e-06	4.04e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—atopic dermatitis	5.81e-06	4.04e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL8—atopic dermatitis	5.7e-06	3.97e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK8—atopic dermatitis	5.58e-06	3.88e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK8—atopic dermatitis	5.56e-06	3.87e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—atopic dermatitis	5.51e-06	3.84e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—atopic dermatitis	5.5e-06	3.83e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—atopic dermatitis	5.45e-06	3.79e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL8—atopic dermatitis	5.43e-06	3.78e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—atopic dermatitis	5.36e-06	3.73e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARA—atopic dermatitis	5.21e-06	3.63e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—atopic dermatitis	5.19e-06	3.62e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—atopic dermatitis	5.17e-06	3.6e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—atopic dermatitis	5.09e-06	3.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—atopic dermatitis	5.08e-06	3.54e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—atopic dermatitis	5.07e-06	3.53e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK8—atopic dermatitis	5.01e-06	3.49e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—atopic dermatitis	4.97e-06	3.46e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—atopic dermatitis	4.95e-06	3.45e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—atopic dermatitis	4.85e-06	3.38e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—atopic dermatitis	4.84e-06	3.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—atopic dermatitis	4.83e-06	3.36e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK8—atopic dermatitis	4.78e-06	3.33e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARA—atopic dermatitis	4.65e-06	3.24e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—atopic dermatitis	4.57e-06	3.18e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARA—atopic dermatitis	4.54e-06	3.16e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK8—atopic dermatitis	4.47e-06	3.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—atopic dermatitis	4.41e-06	3.07e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—atopic dermatitis	4.38e-06	3.05e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARA—atopic dermatitis	4.28e-06	2.98e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARA—atopic dermatitis	4.24e-06	2.95e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—atopic dermatitis	4.19e-06	2.92e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—atopic dermatitis	4.17e-06	2.9e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—atopic dermatitis	4.16e-06	2.9e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—atopic dermatitis	4.12e-06	2.87e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—atopic dermatitis	4.07e-06	2.84e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK8—atopic dermatitis	3.86e-06	2.68e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—atopic dermatitis	3.75e-06	2.61e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—atopic dermatitis	3.75e-06	2.61e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARA—atopic dermatitis	3.63e-06	2.52e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—atopic dermatitis	3.56e-06	2.48e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—atopic dermatitis	3.55e-06	2.47e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—atopic dermatitis	3.2e-06	2.23e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—atopic dermatitis	3.05e-06	2.12e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—atopic dermatitis	2.85e-06	1.99e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARA—atopic dermatitis	2.8e-06	1.95e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—atopic dermatitis	2.46e-06	1.71e-05	CbGpPWpGaD
